Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro

BACKGROUND: The success of anti-TNF biologics for the treatment of rheumatoid arthritis has highlighted the importance of understanding the intracellular pathways that regulate TNF production in the quest for an orally-available small molecule inhibitor. p38 is known to strongly regulate TNF product...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendriks, Bart S, Seidl, Kelly M, Chabot, Jeffrey R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850882/
https://www.ncbi.nlm.nih.gov/pubmed/20230629
http://dx.doi.org/10.1186/1752-0509-4-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850882/
https://www.ncbi.nlm.nih.gov/pubmed/20230629
http://dx.doi.org/10.1186/1752-0509-4-23

Ejemplares similares